Abstract 1944P
Background
T-cell based therapies are currently explored in clinical trials (NCT04044768, NCT01343043) in patients with synovial sarcoma (SySa). These therapies are targeting cancer testis antigens like Melanoma-Associated Antigen 4 (MAGE-A4) or New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1). We explored the molecular epidemiology of these targets using a tissue micro-array (TMA) from clinical SySa samples.
Methods
We created a TMA consisting of 323 cores from 108 clinical samples (≥2 cores/sample) from archival, paraffin-embedded material originating from 91 individual donors. A sarcoma reference pathologist verified the diagnosis of SySa in the donor sample. Most samples (62%) were collected from the primary tumour, 22% and 16% originated from a metastasis or local recurrence. Slides were stained with MAGE-A4 antibody (#82491, dilution 1:100, Cell Signaling) and NY-ESO-1 antibody (clone E978, dilution 1:200, Sigma), during an overnight incubation. Normal human testis tissue was used as a positive control. Expression of each core was scored as an H-score, defined as: (% stained cells at 0 intensity) × 0 + (% stained cells at 1+ intensity) × 1 + (% stained cells at 2+ intensity) × 2 + (% stained cells at 3+ intensity) × 3. The average of the H-scores from the cores corresponding to the same tumour sample was used for subsequent analyses. Expression of the target was defined as an average H-score ≥ 1 and high expression was defined as an average H-score > 100. Kruskal-Wallis test was used for the statistical analyses.
Results
Expression of NY-ESO-1 and MAGE-A4 was found in 50.9% (55/108) and 68.5% (74/108) of TMA samples. High expression was noticed in 20/108 samples (18.5%) for NY-ESO-1 and in 25/108 samples (23.1%) for MAGE-A4. In 77.8% of the samples there is at least one of these cancer testis antigens expressed. There was no correlation between the expression level and disease status at the sampling moment, nor with clinical outcome of the patient. Additionally, there was no correlation between the expression level and the size of the original tumour.
Conclusions
MAGE-A4 and NY-ESO-1 are expressed in a clinically relevant proportion of SySa cases represented in our TMA, this supports the utility of these antigens as targets for novel cell-based therapies in this disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1960P - Clinical outcomes of the patients with alveolar soft part sarcoma developed brain metastasis
Presenter: Yu Toda
Session: Poster session 15
1961P - Prevalence of diagnostic discrepancies in soft tissue and bone tumors from initial diagnosis to referral center
Presenter: Khomsit Thongthammachat
Session: Poster session 15
1963P - Comprehensive profiling of chordoma reveals tumor microenvironment subtypes and unique molecular findings
Presenter: Marina Voropaeva
Session: Poster session 15
1964P - Biomimetics of three-dimensional (3D) osteosarcoma (OS) models: A scoping review
Presenter: Vinesh Sandhu
Session: Poster session 15
1965P - Transcriptional analysis of immune microenvironment of chordomas of the skull base and mobile spine
Presenter: Jason Roszik
Session: Poster session 15
1966P - Extending the interval of denosumab treatment for unresectable giant cell tumor of bone
Presenter: Toshiyuki Kunisada
Session: Poster session 15
1967P - A single-arm multicenter trial of the combination of anlotinib with chemotherapy in patients with stage IIb classic osteosarcoma of the extremity
Presenter: Fan Tang
Session: Poster session 15
1968P - Metastatic Ewing sarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15
1969P - Intratumoral immune infiltrates in chondrosarcoma (ChS)
Presenter: Piotr Rutkowski
Session: Poster session 15
1970P - Metastatic chondrosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: coline ducrot
Session: Poster session 15